Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
17.81 USD | +1.60% | +0.62% | -31.79% |
Apr. 30 | Zebra Technologies first-quarter results beat estimates | RE |
Apr. 26 | CVS Omnicare staff in Las Vegas vote to join new union | RE |
Summary
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.15 for the 2024 fiscal year.
- The company appears to be poorly valued given its net asset value.
- The company has a low valuation given the cash flows generated by its activity.
- This company will be of major interest to investors in search of a high dividend stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Drug Retailers
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-31.79% | 15.36B | B- | ||
-21.99% | 12.45B | B | ||
-22.64% | 6.75B | B | ||
+9.74% | 6.14B | C | ||
-10.91% | 6.07B | C+ | ||
+0.58% | 4.78B | D- | ||
+59.24% | 4.53B | - | C | |
-9.00% | 3.81B | B | ||
-12.53% | 3.43B | C- | ||
-7.34% | 3.09B | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- WBA Stock
- Ratings Walgreens Boots Alliance, Inc.